Evaluating Medical Therapy for Calcific Aortic Stenosis: JACC State-of-the-Art Review
Overview
Authors
Affiliations
Despite numerous promising therapeutic targets, there are no proven medical treatments for calcific aortic stenosis (AS). Multiple stakeholders need to come together and several scientific, operational, and trial design challenges must be addressed to capitalize on the recent and emerging mechanistic insights into this prevalent heart valve disease. This review briefly discusses the pathobiology and most promising pharmacologic targets, screening, diagnosis and progression of AS, identification of subgroups that should be targeted in clinical trials, and the need to elicit the patient voice earlier rather than later in clinical trial design and implementation. Potential trial end points and tools for assessment and approaches to implementation and design of clinical trials are reviewed. The efficiencies and advantages offered by a clinical trial network and platform trial approach are highlighted. The objective is to provide practical guidance that will facilitate a series of trials to identify effective medical therapies for AS resulting in expansion of therapeutic options to complement mechanical solutions for late-stage disease.
Transcatheter Aortic Valve Implantation in Patients with Previous Mitral Valve Surgery-Review.
Olasinska-Wisniewska A, Misterski M, Grygier M, Konstanty-Kalandyk J, Urbanowicz T, Lesiak M J Clin Med. 2025; 14(3).
PMID: 39941404 PMC: 11818685. DOI: 10.3390/jcm14030735.
Park J, Kim J, Jeon J, Yoon Y, Jang Y, Jeong H EBioMedicine. 2025; 112:105560.
PMID: 39842286 PMC: 11794175. DOI: 10.1016/j.ebiom.2025.105560.
Calcific aortic stenosis: omics-based target discovery and therapy development.
Blaser M, Back M, Luscher T, Aikawa E Eur Heart J. 2024; 46(7):620-634.
PMID: 39656785 PMC: 11825147. DOI: 10.1093/eurheartj/ehae829.
AI-Enhanced Prediction of Aortic Stenosis Progression: Insights From the PROGRESSA Study.
Sanabria M, Tastet L, Pelletier S, Leclercq M, Ohl L, Hermann L JACC Adv. 2024; 3(10):101234.
PMID: 39309663 PMC: 11416525. DOI: 10.1016/j.jacadv.2024.101234.
Tastet L, Shen M, Capoulade R, Arsenault M, Bedard E, Abdoun K JACC Adv. 2024; 3(10):101267.
PMID: 39296821 PMC: 11408378. DOI: 10.1016/j.jacadv.2024.101267.